International variation in the use of evidence-based medicines for acute coronary syndromes.

[1]  Acute myocardial infarction: pre-hospital and in-hospital management , 2005 .

[2]  Robert M Califf,et al.  Early statin initiation and outcomes in patients with acute coronary syndromes. , 2002, JAMA.

[3]  Carl J Pepine,et al.  ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients , 2002, Journal of the American College of Cardiology.

[4]  V. Hasselblad,et al.  Seeking the optimal aspirin dose in acute coronary syndromes. , 2002, The American journal of cardiology.

[5]  W Klein,et al.  Management of acute coronary syndromes. Variations in practice and outcome; findings from the Global Registry of Acute Coronary Events (GRACE). , 2002, European heart journal.

[6]  AndrewJ. S. Coats.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial , 2002, The Lancet.

[7]  Werner Klein,et al.  Early Statin Initiation and Outcomes in Patients With Acute Coronary Syndromes , 2002 .

[8]  S. Yusuf.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Commentary , 2002 .

[9]  Alastair Baker,et al.  Crossing the Quality Chasm: A New Health System for the 21st Century , 2001, BMJ : British Medical Journal.

[10]  M. Flather,et al.  Potential impact of socioeconomic differences on clinical outcomes in international clinical trials. , 2001, American heart journal.

[11]  Second Symphony Investigators.  Randomized Trial of Aspirin, Sibrafiban, or Both for Secondary Prevention After Acute Coronary Syndromes , 2001, Circulation.

[12]  Kukin Ml.  The Heart Outcomes Prevention Evaluation Study. , 2001, Current cardiology reports.

[13]  G. Montalescot,et al.  Percutaneous Coronary Intervention After Subcutaneous Enoxaparin Pretreatment in Patients With Unstable Angina Pectoris , 2001, Circulation.

[14]  B. Horne,et al.  Usefulness of in-hospital prescription of statin agents after angiographic diagnosis of coronary artery disease in improving continued compliance and reduced mortality. , 2001, The American journal of cardiology.

[15]  David R. Wood,et al.  Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme. , 2001, European heart journal.

[16]  R. Califf,et al.  Temporal evolution in the management of acute ST elevation myocardial infarction: the seven-year GUSTO experience from canada and the united states. The North American GUSTO-I and GUSTO-III investigators. , 2000, The Canadian journal of cardiology.

[17]  U Keil,et al.  The ENACT study: a pan-European survey of acute coronary syndromes. European Network for Acute Coronary Treatment. , 2000, European heart journal.

[18]  M. Cohen,et al.  Inter-regional differences and outcome in unstable angina; analysis of the international ESSENCE trial. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-wave Coronary Events. , 2000, European heart journal.

[19]  G. Specchia,et al.  Management of acute coronary syndromes: acute coronary syndromes without persistent ST segment elevation; recommendations of the Task Force of the European Society of Cardiology. , 2000, European heart journal.

[20]  A. Adgey,et al.  Management of acute coronary syndromes , 2000, BMJ : British Medical Journal.

[21]  R. Califf,et al.  Geographic variability in outcomes within an international trial of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes. Results from PURSUIT. , 2000, European heart journal.

[22]  R. Califf,et al.  Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: a randomised trial , 2000, The Lancet.

[23]  S. Yusuf,et al.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. , 2000 .

[24]  L. Kohn,et al.  COMMITTEE ON QUALITY OF HEALTH CARE IN AMERICA , 2000 .

[25]  J S Alpert,et al.  1999 update: ACC/AHA Guidelines for the Management of Patients With Acute Myocardial Infarction: Executive Summary and Recommendations: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction) , 1999, Circulation.

[26]  L. Newby,et al.  Long-term oral platelet glycoprotein IIb/IIIa receptor antagonism with sibrafiban after acute coronary syndromes: Study design of the Sibrafiban versus aspirin to Yield Maximum Protection from ischemic Heart events post-acute cOroNary sYndromes (SYMPHONY) trial , 1999 .

[27]  F. McAlister,et al.  The Treatment and Prevention of Coronary Heart Disease in Canada: Do Older Patients Receive Efficacious Therapies? , 1999 .

[28]  N. Sharpe.  Translation of clinical trial results into practice. , 1998, European heart journal.

[29]  H. Krumholz,et al.  National use and effectiveness of beta-blockers for the treatment of elderly patients after acute myocardial infarction: National Cooperative Cardiovascular Project. , 1998, JAMA.

[30]  C. Camargo,et al.  Elderly patients receive less aggressive medical and invasive management of unstable angina: potential impact of practice guidelines. , 1998, Archives of internal medicine.

[31]  E. Raftery,et al.  The association between cardiac events and myocardial ischaemia following thrombolysis in acute myocardial infarction and the impact of carvedilol. , 1996, European heart journal.

[32]  Richard P. Lewis,et al.  ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). , 1996, Journal of the American College of Cardiology.

[33]  Walker,et al.  Collaborative overview of randomised trials of antiplatelet therapy Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients , 1994 .

[34]  E. Braunwald.  Unstable angina : diagnosis and management , 1994 .

[35]  M. LeWinter,et al.  Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study. , 1983, The New England journal of medicine.

[36]  K.,et al.  Propranolol therapy in patients with acute myocardial infarction: the Beta-Blocker Heart Attack Trial. , 1983, Circulation.